Physician profile
Wayne Beauford
NPI 1043232606
$2,419.04
in general payments reported to CMS, 2019-2025
30 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $247 · 2021: $696 · 2022: $356 · 2023: $251 · 2024: $371 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $289.34 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Welch Allyn | $263.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $234.59 | 2020-2024 | Breztri, Farxiga |
| Baxter Healthcare | $229.00 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $172.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.03 | 2020-2021 | |
| Mylan Specialty L.P. | $143.72 | 2023-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.61 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Novo Nordisk INC | $100.63 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $82.09 | 2020-2022 | |
| Amgen INC. | $77.80 | 2019-2023 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $59.52 | 2019-2020 | |
| Boston Scientific Corporation | $52.83 | 2024 | Watchman Flx |
| Abbvie INC. | $52.66 | 2023-2024 | Linzess |
| Viatris Specialty LLC | $50.40 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $47.92 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $38.10 | 2021 | |
| Aimmune Therapeutics, INC. | $37.33 | 2025 | Zenpep |
| Genzyme Corporation | $36.86 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.66 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.14 | 2024 | Rexulti |
| Insmed, INC. | $21.77 | 2025 | Arikayce |
| Pfizer INC. | $14.73 | 2023 | |
| Collegium Pharmaceutical, INC. | $13.31 | 2019 | |
| Hikma Pharmaceuticals USA | $13.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.08 | 2019 | |
| Shionogi INC | $12.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.36 | 2021 | |
| Amarin Pharma, INC. | $11.27 | 2021 | |
| Inogen, INC. | $10.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Beauford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.